Novel Psma-Binding Agents and Uses Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses novel compounds designed to specifically bind with Prostate-Specific Membrane Antigen (PSMA), which is overexpressed in prostate and some other cancer cells. These compounds are engineered to also bind human serum albumin (HSA), allowing for enhanced circulation time and improved delivery to tumor cells. The agents are designed for dual use: as imaging agents (radiopharmaceuticals for diagnostic scans like PET or SPECT) and as targeted therapies when labeled with therapeutic radionuclides. The compounds feature modular structures with a PSMA-targeting component, an albumin-binding moiety, and a chelating group for complexing different radioactive isotopes.

Use CasesContent extracted from patent full text and abstract with AI.

• Diagnosis of prostate cancer via targeted imaging (PET/SPECT) using radiolabeled PSMA ligands.
• Therapeutic treatment of prostate cancer by delivering radiation directly to cancer cells via targeted radiopharmaceuticals.
• Imaging and/or treatment of other cancers with PSMA expression, such as pancreatic, renal, or bladder cancer.
• Monitoring recurrence or metastasis of prostate or related cancers via imaging.
• Development of theranostic approaches (combined diagnostic and therapeutic regimens) for individualized cancer management.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly selective targeting of PSMA-expressing tumor cells, enabling more accurate diagnosis and treatment.
• Enhanced blood circulation time and tumor uptake due to albumin binding, improving efficacy and possibly reducing required dosages.
• Flexible modular design allows use with various diagnostic or therapeutic radionuclides, adapting to both imaging and therapy.
• Potential to reduce side effects compared to less specific treatments, as lower uptake in non-target tissues is expected.
• May enable early diagnosis and precise monitoring of disease progression or therapeutic response in prostate and related cancers.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.